Contact: Vincent La Terza  
Location: NeurOp, Inc.  
Email: vlaterza@neuropinc.com  
Tel: 404 941 2360  
Website: www.neuropinc.com

**Company Profile**

**Industry Sector:** Biopharmaceuticals

**Company Overview:** NeurOp, Inc. is a preclinical stage biopharmaceutical company developing new medicines to treat central nervous system (CNS) disorders, including major depression, neuropathic pain, ischemia, and schizophrenia.

**Target Market(s):** We provide preclinical and early clinical stage new medicines to large pharmaceutical firms. NeurOp is partnered with BMS on its depression and pain programs and has internal programs directed towards stroke and schizophrenia. The global market for antidepressants is about $19B/year; for pain drugs about $8B/year; for drugs to protect brain from strokes $5B and for schizophrenia about $18B.

**Management**

**Leadership:** Dr. Barney Koszalka has overseen numerous drug development programs in the past, having contributed in a significant manner to the discovery, development and lifecycle management of twelve marketed drugs. His extensive background as a senior executive in large pharma is a major asset. Vincent La Terza, who heads business development, has a legal background and has been involved in licensing and growing start-ups for years. Dr Scott Myers directs NeurOp’s discovery program. Scott trained in the labs of NeurOp’s founders and has been working on the NMDAR pathway since 2005. NeurOp’s BOD includes the former CFO of Trimeris and former CEO of Solvay.

**Scientific Advisory Board:** Two of NeurOp’s founders, Ray Dingledine, Ph.D. and James McNamara MD are members of the National Academy of Sciences and the third, Steve Traynelis, Ph.D. is also a world renowned neuropharmacologist. The company has assembled a blue chip team comprised of industry veterans to advise it in medicinal chemistry and all aspects of drug development.

**Key Value Drivers**

**Technology:** Our discovery assets include in vitro and in vivo safety and efficacy assays and models. We possess substantial expertise in pharmacology, drug development and a novel approach to enhance the safety and efficacy of NMDAR antagonists for ischemia.

**Competitive Advantage:** NeurOp has unsurpassed expertise regarding the neuropharmacology of a key signaling pathway in the brain called the NMDAR pathway (NMDAR). Studies in animals and man show that modulation of this pathway offers benefits previously unattainable; including very fast onset of relief from depression and pain, and potent protection of brain tissue during, and in the aftermath of cerebral ischemia. NeurOp’s drugs are protected by a robust and growing worldwide patent portfolio.

**Plan and Strategy:** Develop programs through proof of concept and partner. Exit via M&A in about 2015. Support from NINDS for our ischemia program remains crucial. NIMH is supporting our schizophrenia program.

**Product Pipeline**

<table>
<thead>
<tr>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeurOp/BMS</td>
<td>Dep. Drug</td>
<td>IND</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Pain drug</td>
<td>IND</td>
<td>Phase 1</td>
<td></td>
</tr>
<tr>
<td>NeurOp</td>
<td>Internal Stroke</td>
<td>IND</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>optimize leads</td>
<td>select candidate</td>
<td>IND</td>
</tr>
</tbody>
</table>